Alamar Biosciences, Inc.
ALMRHealthcare|Biotechnology|US
$28.05
+1.15 (+4.26%)
DCF Value
$22.60
Tangible Book / Share
$4.37
Cash / Share
$3.28
About
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Stock Price
+27.5%(1Y)
1M
+8.3%
3M
-1.4%
6M
+17.1%
YTD
+27.5%
1Y
+27.5%
3Y
+27.5%
5Y
+27.5%
Pipeline Summary
1 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
By Invitation: 1
Key Facts
Market Cap$1.95B
Employees222
CEOYuling Luo
IPO DateApr 17, 2026
Beta-6.18
52-Week Range$18.85 – $39.61
Avg Volume495,674
ExchangeNASDAQ
Websitewww.alamarbio.com
Ownership
Float51.6%
Shares Outstanding69.4M
Recent Insider Trades
Qiming Corporate GP VI, Ltd.SELL
Nov 3, 202672,301 shares @ $29.89
Qiming Corporate GP VI, Ltd.SELL
Nov 3, 202620,196 shares @ $29.89
Qiming Corporate GP VI, Ltd.SELL
Nov 3, 202616,870 shares @ $29.89
Qiming Corporate GP VI, Ltd.SELL
Nov 3, 20261,946 shares @ $29.89
Qiming Corporate GP VI, Ltd.SELL
Oct 30, 202648,659 shares @ $29.93
Peers
Recent News
Alamar Biosciences (NASDAQ:ALMR) Stock: Insider Corporate Gp Vi Ltd. Qiming Sells 111,313 Shares
Nov 7, 2026 · defenseworld.net
Alamar Biosciences to Participate in Upcoming Investor Conferences
Nov 4, 2026 · globenewswire.com
Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript
Nov 3, 2026 · seekingalpha.com
Alamar Biosciences Q3 Earnings Call Highlights
Nov 3, 2026 · marketbeat.com
Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Nov 3, 2026 · zacks.com
Data last updated: Nov 9, 2026, 03:53 AM